Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Report calls for action to increase vet med pipeline

Regulatory measures across the EU have constrained the availability of an adequate range of veterinary medicines at the same time as the freer movement of animals and food products derived from them within the single market has raised the challenge of animal disease, notes an influential report. While the need for consumer protection and food safety is paramount, the rising regulatory burden of ensuring that animal medicines match the quality, efficacy and safety of human products, while ensuring that residues in food products are acceptably safe levels is difficult to achieve in a commercial environment. The cost of this process means that many products with limited sales potential are either not marketed, or are limited to the major economic species. This is especially true of the agricultural sector, accounting for around half of the market, where returns have been under pressure for some years. This is driving commercial R&D to the bloodstock and companion animal parts of the market where the potential rewards are much greater.


What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts